Associations and indications of Ki67 expression with clinicopathological parameters and molecular subtypes in invasive breast cancer: A population-based study

Sun,Jinzhong; Chen,Chuang; Wei,Wen; Zheng,Hongmei; Yuan,Jingping; Tu,Yi; Yao,Feng; Wang,Lijun; Yao,Xiaoli; Li,Juanjuan; Li,Yan; Sun,Shengrong

doi:10.3892/ol.2015.3461

Associations and indications of Ki67 expression with clinicopathological parameters and molecular subtypes in invasive breast cancer: A population-based study

Authors:
- Jinzhong Sun
- Chuang Chen
- Wen Wei
- Hongmei Zheng
- Jingping Yuan
- Yi Tu
- Feng Yao
- Lijun Wang
- Xiaoli Yao
- Juanjuan Li
- Yan Li
- Shengrong Sun
View Affiliations

Affiliations: Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China, Department of Breast Surgery, Hubei Cancer Hospital, Wuhan, Hubei 430079, P.R. China, Department of Oncology, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Wuhan, Hubei 430071, P.R. China
Published online on: July 6, 2015 https://doi.org/10.3892/ol.2015.3461
Pages: 1741-1748

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ki67 has potential prognostic and predictive values for breast cancer patients, and has become an important biomarker in routine clinical practice. The aims of the present study were to investigate the distribution of Ki67 expression and its correlation with other clinicopathological parameters in central China. In total, 1,259 patients with newly-diagnosed invasive breast cancer were included in the present study. The clinical information was obtained from the electronic medical records. The expression levels of Ki67, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) were detected by immunohistochemical analysis. The associations between Ki67 scores and other prognostic factors were evaluated as continuous and categorical variables. The mean value of the Ki67 scores of all patients was 31%. In total, ~36% (456/1,259) of the patients demonstrated a low expression of Ki67. A statistically significant correlation was identified between the mean Ki67 scores and the lymph node status, tumor grade, ER, PR and HER2 status, and clinical stage or molecular subtypes (all P<0.001). When Ki67 was categorized into high (>14%) and low (≤14%) level groups, the χ2 test was used to verify these results. The Ki67 scores demonstrated no statistically significant differences between the HER2‑positive (non‑luminal) and three negative subtypes, with the exception of patients with a tumor size of >2 cm (P=0.02). In conclusion, the results revealed the presence of significant correlations between Ki67 and other clinicopathological parameters.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Gerdes J, Schwab U, Lemke H and Stein H: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 31:13–20. 1983. View Article : Google Scholar : PubMed/NCBI
3	Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U and Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 133:1710–1715. 1984.PubMed/NCBI
4	Gerdes J, Li L, Schlueter C, et al: Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol. 138:867–873. 1991.PubMed/NCBI
5	de Azambuja E, Cardoso F, de Castro G Jr, et al: Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer. 96:1504–1513. 2007. View Article : Google Scholar : PubMed/NCBI
6	Kontzoglou K, Palla V, Karaolanis G, et al: Correlation between Ki67 and breast cancer prognosis. Oncology. 84:219–225. 2013. View Article : Google Scholar : PubMed/NCBI
7	Jones RL, Salter J, A'Hern R, et al: Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat. 119:315–323. 2010. View Article : Google Scholar : PubMed/NCBI
8	Ellis MJ, Coop A, Singh B, et al: Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res. 63:6523–6531. 2003.PubMed/NCBI
9	Dowsett M, Smith IE, Ebbs SR, et al IMPACT Trialists: Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res. 11:951s–958s. 2005.PubMed/NCBI
10	Dowsett M, Nielsen TO, A'Hern R, et al International Ki-67 in Breast Cancer Working Group: Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 103:1656–1664. 2011. View Article : Google Scholar : PubMed/NCBI
11	Cheang MC, Chia SK, Voduc D, et al: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 101:736–750. 2009. View Article : Google Scholar : PubMed/NCBI
12	Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B and Senn HJ: Role: Panel MembersStrategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 22:1736–1747. 2011. View Article : Google Scholar : PubMed/NCBI
13	Haroon S, Hashmi AA, Khurshid A, et al: Ki67 index in breast cancer: correlation with other prognostic markers and potential in pakistani patients. Asian Pac J Cancer Prev. 14:4353–4358. 2013. View Article : Google Scholar : PubMed/NCBI
14	Pinder SE, Wencyk P, Sibbering DM, et al: Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer. 71:146–149. 1995. View Article : Google Scholar : PubMed/NCBI
15	Midulla C, De Iorio P, Nagar C, et al: Immunohistochemical expression of p53, nm23-HI, Ki67 and DNA ploidy: correlation with lymph node status and other clinical pathologic parameters in breast cancer. Anticancer Res. 19:4033–4037. 1999.PubMed/NCBI
16	No authors listed. The World Health Organization. Histological typing of breast tumors. Neoplasma. 30:113–123. 1983.PubMed/NCBI
17	Robbins P, Pinder S, de Klerk N, et al: Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol. 26:873–879. 1995. View Article : Google Scholar : PubMed/NCBI
18	Edge SB, Byrd DR, Compton CC, et al: AJCC Cancer Staging Manual. 7th. Springer; New York, NY, USA: 2009
19	Hammond ME, Hayes DF, Dowsett M, et al: American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 28:2784–2795. 2010. View Article : Google Scholar : PubMed/NCBI
20	Wolff AC, Hammond ME, Hicks DG, et al American Society of Clinical Oncology; College of American Pathologists: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practise guideline update. J Clin Oncol. 31:3997–4013. 2013. View Article : Google Scholar : PubMed/NCBI
21	Fasching PA, Heusinger K, Haeberle L, et al: Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer. 11:4862011. View Article : Google Scholar : PubMed/NCBI
22	Heusinger K, Jud SM, Haeberle L, et al: Association of mammographic density with the proliferation marker Ki-67 in a cohort of patients with invasive breast cancer. Breast Cancer Res Treat. 135:885–892. 2012. View Article : Google Scholar : PubMed/NCBI
23	Ferguson NL, Bell J, Heidel R, et al: Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women. Breast J. 19:22–30. 2013. View Article : Google Scholar : PubMed/NCBI
24	Reyal F, Hajage D, Savignoni A, et al: Long-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinoma. PLoS One. 8:e559012013. View Article : Google Scholar : PubMed/NCBI
25	Yerushalmi R, Woods R, Ravdin PM, Hayes MM and Gelmon KA: Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 11:174–183. 2010. View Article : Google Scholar : PubMed/NCBI
26	Kontzoglou K, Palla V, Karaolanis G, et al: Correlation between Ki67 and breast cancer prognosis. Oncology. 84:219–225. 2013. View Article : Google Scholar : PubMed/NCBI
27	Mitrović O, Čokić V, Đikić D, et al: Correlation between ER, PR, HER-2, Bcl-2, p53, proliferative and apoptotic indexes with HER-2 gene amplification and TOP2A gene amplification and deletion in four molecular subtypes of breast cancer. Target Oncol. 9:367–379. 2014. View Article : Google Scholar : PubMed/NCBI